What it is: A synthetic version of the first 29 amino acids of GHRH, the signal your hypothalamus sends to tell the pituitary to produce growth hormone.
Research suggests: The most extensively studied GH secretagogue, with a prior approval history for GH deficiency in children and widespread use in adult anti-aging protocols.
Best for: Growth hormone optimization and anti-aging researchers
Key thing to know: The only GH secretagogue with a prior regulatory approval history; stimulates the body's own GH production rather than introducing synthetic hormone from outside.
What is Sermorelin?
Sermorelin is a synthetic analog of GHRH (GHRH 1-29) and the oldest, most studied growth hormone secretagogue. It has a prior approval history for growth hormone deficiency in children — the only compound here to have earned regulatory approval. Unlike synthetic HGH, it stimulates the pituitary to release its own GH rather than adding exogenous hormone.
Researchers have studied sermorelin for growth hormone deficiency correction, age-related GH decline, body composition optimization, sleep quality improvement, particularly slow-wave sleep, and recovery support in both clinical and research populations. Its long safety and efficacy track record makes it a reference point for the broader GH secretagogue category.
How it works.
In research, the proposed mechanism has several parts.
GHRH receptor: Sermorelin binds directly to GHRH receptors in the anterior pituitary, triggering natural, pulsatile growth hormone release. The pituitary secretes GH, which travels to the liver to stimulate IGF-1 production — the downstream mediator of many of GH's effects on muscle, fat metabolism, bone density, and cellular repair.
Versus direct HGH: The key distinction from direct HGH is that sermorelin works through the body's own pituitary. Because GH release stays subject to normal negative feedback — when IGF-1 rises enough, somatostatin reduces pituitary GH output — the system keeps its regulatory checks, with the body deciding how much releases and when to stop.
Feedback preservation: This feedback preservation is clinically significant: studies indicate it reduces the risk of GH excess and side effects versus direct HGH injection, where exogenous hormone bypasses feedback entirely. Research has also documented positive effects on slow-wave (deep) sleep, where natural GH release is highest, suggesting it may partly restore the age-related decline in that GH pulse.
What the research shows.
The research evidence breaks down as follows.
An established record: Sermorelin has the longest, most established research history of any GH secretagogue. It received regulatory approval for pediatric growth hormone deficiency — a bar no other GH secretagogue has cleared. Multiple published clinical studies document increased GH and IGF-1, improved body composition, better sleep quality (particularly slow-wave sleep), and recovery support in children and adults.
Adult studies: Adult studies have examined sermorelin's effects on age-related GH decline, sometimes called somatopause, with findings showing meaningful improvements in GH pulsatility, IGF-1 levels, body fat, and lean mass. Its safety profile across decades of clinical use is well characterized, with no serious safety signals emerging from the long-term pediatric literature or from adult research use.
Approval context: Important context: the approval was voluntarily withdrawn by the original manufacturer for commercial reasons, not safety or efficacy reasons. The clinical data remains in the peer-reviewed literature and continues to inform research and clinical practice. Compounded versions are used in clinical settings, though quality varies across compounding pharmacies.
Biomarkers to review first.
Research protocols for sermorelin typically reference the following biomarkers as baseline context. Testing these before exploring this peptide gives you and your healthcare provider the most relevant starting information.
See the full lab testing guide →What it's commonly researched with.
Sermorelin is studied in combination with other GH secretagogues that work through complementary receptor pathways, and with compounds targeting metabolic and longevity endpoints where GH axis optimization is relevant. The entries below reflect what appears in research literature, not recommendations for use without clinical supervision.
Goals & biomarkers connected to this peptide.
Go deeper
A research overview of the baseline biomarkers used to establish context before exploring peptide research, viewed through a longevity lens.
Read Research →